Aberrancy in cell cycle progression is one of the fundamental mechanisms underlying tumorigenesis, making regulators of the cell cycle machinery rational anticancer therapeutic targets. A growing body of evidence indicates that the cell cycle regulatory pathway integrates into other hallmarks of cancer, including metabolism remodeling and immune escape. Thus, therapies against cell cycle machinery components can not only repress the division of cancer cells, but also reverse cancer metabolism and restore cancer immune surveillance. Besides the ongoing effects on the development of small molecule inhibitors (SMIs) of the cell cycle machinery, proteolysis targeting chimeras (PROTACs) have recently been used to target these oncogenic proteins related to cell cycle progression. Here, we discuss the rationale of cell cycle targeting therapies, particularly PROTACs, to more efficiently retard tumorigenesis.

细胞周期进程的异常是肿瘤发生的基本机制之一，使细胞周期机制的调节成为合理的抗癌治疗靶点。越来越多的证据表明，细胞周期调节通路整合到癌症的其他标志中，包括代谢重塑和免疫逃逸。因此，针对细胞周期机制成分的治疗不仅可以抑制癌细胞的分裂，还可以逆转癌症代谢并恢复癌症免疫监视。除了对细胞周期机制的小分子抑制剂 (SMI) 的发展产生持续影响外，蛋白水解靶向嵌合体 (PROTAC) 最近已被用于靶向这些与细胞周期进程相关的致癌蛋白。在这里，我们讨论细胞周期靶向疗法的基本原理，